In this study, we sought to identify the therapeutic vulnerability of erlotinib-resistant HCC827-ErlR cells and identified HSF1 as a potential target to overcome EGFR-TKI resistance in NSCLC tumors. Here, HSF1 is linked to non-small cell lung carcinoma.